CNBX Pharmaceuticals Inc. (CNBX) FCF Margin (2016 - 2024)
CNBX Pharmaceuticals' (CNBX) quarterly FCF Margin came in at 306.12% in Q1 2024, down 274.83% on a QoQ basis from 81.67% in Q4 2023.
CNBX Pharmaceuticals Inc. (CNBX) FCF Margin (2016 - 2024) Analysis & Trends
CNBX Pharmaceuticals (CNBX) has 8 years of FCF Margin data on file, last reported at 306.12% in Q1 2024.
- Quarterly FCF Margin changed N/A year-over-year to 306.12% in Q1 2024, while the trailing twelve-month figure through Nov 2024 was 520.46% (down 50252.0% YoY) and the FY2024 annual result came in at 188.71%, down 16128.0% from the prior year.
- FCF Margin retreated to 306.12% in Q1 2024, from 81.67% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 20.52% in Q3 2023 to a low of 55628.24% in Q1 2020.
- A 4-year average of 15325.51% and a median of 404.5% in 2022 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 1121676 bps in 2020, down 2202764 bps in 2020.
- Tracing CNBX's FCF Margin over 4 years: stood at 32350.93% in 2020, then jumped by 98 bps to 502.88% in 2022, then surged by 84 bps to 81.67% in 2023, then tumbled by 275 bps to 306.12% in 2024.
- The last three FCF Margin figures came in at 306.12% (Q1 2024), 81.67% (Q4 2023), and 20.52% (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 29, 2024 | -306.12% |
| Nov 30, 2023 | -81.67% |
| Aug 31, 2023 | 20.52% |
| May 31, 2023 | -5.99% |
| Aug 31, 2022 | -502.88% |
| Aug 31, 2020 | -32,350.93% |
| May 31, 2020 | -33,748.73% |
| Feb 29, 2020 | -55,628.24% |
| Nov 30, 2019 | -43,984.44% |
| Aug 31, 2019 | -43,567.69% |
| May 31, 2019 | -41,249.81% |
| Feb 28, 2019 | -33,600.60% |
| Nov 30, 2018 | -22,496.55% |
| Aug 31, 2018 | -27,799.53% |
| May 31, 2018 | -19,076.08% |
| Feb 28, 2018 | -55,618.80% |
| Nov 30, 2017 | -26,020.71% |
| Aug 31, 2017 | -13,176.38% |
| May 31, 2017 | -18,764.48% |
| Feb 28, 2017 | -13,631.05% |